Mylan extends recall as stray tablets of diabetes med show up in bottles of an antidepressant

Mylan is recalling lots of the Type 2 diabetes med Glipizide and the antidepressant Mirtazapine after stray tablets were discovered in bottles of the meds.

Some weeks back, generics maker Mylan recalled about 1,300 bottles, containing more than 1.3 million tablets, of the 5-mg dose of the Type 2 diabetes med Glipizide. The recall was voluntarily initiated because there was a chance that tablets in a 10-mg dose might have gotten into the bottles. Now the drugmaker has issued two more recalls of an entirely different med that might also contain some of the stray tablets.

According to the FDA Enforcement reports, Mylan has recently included in the class II voluntary recall 37,445 bottles of 500-count and 1,000-count tablets of Mirtazapine, as well as 58, blister packs of the drug in in 100-count sizes because they may contain Glipizide tablets. Mirtazapine is an antidepressant.

According to the FDA report, the drugs were all manufactured by Mylan at its facility in Morgantown, West Virginia.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

While not common, this kind of issue does arise on packaging lines. In 2014, for example, Pfizer recalled 221,000 bottles of Pristiq after a single 100-mg tablet of the antidepressant was found in a 50-mg bottle.

Months before, Pfizer recalled more than 100,000 bottles of its antidepressant Effexor XR after a bottle was found to contain a tablet of the heart drug Tikosyn. The drugmaker said the risk that any other bottles might be affected was slim, but it decided to recall the three lots of Effexor XR as a precaution since all three were run on the same packaging line.


Suggested Articles

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.